AstraZeneca has invested $200m in a new manufacturing facility in China Medical City, Taizhou, Jiangsu province. The new plant will manufacture both intravenous and oral solid medicines.According to the company, the new plant will help meet the rising demand for its products in China besides extending its availability in urban and rural communities that have limited access to established medicines. AstraZeneca China president Mark Mallon said the manufacturing facility will meet the medical needs of Chinese patients with medicines that are locally produced.”In particular, it will help us to reach out to more of the estimated 900 million people in urban and rural communities who have had less access to high quality medicines,” Mallon added.The facility is expected to be completed by the end of 2013.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Related stories
- Advertisement -
Latest stories
Related stories
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access theMedia Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
